Compile Data Set for Download or QSAR
Report error Found 137 Enz. Inhib. hit(s) with all data for entry = 10418
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534197(WO2022081973, Example 1 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  570nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534198(WO2022081973, Example 2 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  5.00E+3nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534199(WO2022081973, Example 3 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  350nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534200(WO2022081973, Example 4 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  540nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534201(WO2022081973, Example 67 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  50nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534202(WO2022081973, Example 6 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  570nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534203(WO2022081973, Example 7 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  360nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534204(WO2022081973, Example 8 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  160nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534205(WO2022081973, Example 9 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  490nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534206(WO2022081973, Example 10 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  55nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534207(WO2022081973, Example 11 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  47nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534208(WO2022081973, Example 12 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  240nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534209(WO2022081973, Example 13 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  240nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534210(WO2022081973, Example 14 | 2-(((2R)-1-(((((2R,3S,4...)
Affinity DataEC50:  53nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534211(WO2022081973, Example 15 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  140nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534212(WO2022081973, Example 16 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  100nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534213(WO2022081973, Example 17 | (2R)-1-(((((2R,3S,4R,5R...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534214(WO2022081973, Example 18 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  69nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534215(WO2022081973, Example 19 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  210nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534216(WO2022081973, Example 66 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  200nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534217(WO2022081973, Example 21 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  250nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534218(WO2022081973, Example 22 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  150nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534219(WO2022081973, Example 23 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  83nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534220(WO2022081973, Example 24 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  73nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534221(WO2022081973, Example 25 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  5.00E+3nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534222(WO2022081973, Example 26 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  5.00E+3nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534223(WO2022081973, Example 27 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  5.00E+3nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534224(WO2022081973, Example 28 | O-(((2R,3S,4R,5R)-5-(4-...)
Affinity DataEC50:  190nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534225(WO2022081973, Example 29 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  70nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534226(WO2022081973, Example 30 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  130nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534227(WO2022081973, Example 31 | 2-(((2R)-1-(((((2R,3S,4...)
Affinity DataEC50:  260nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534228(WO2022081973, Example 32 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  40nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534229(WO2022081973, Example 33 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534230(WO2022081973, Example 34 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  11nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534231(WO2022081973, Example 35 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  95nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534232(WO2022081973, Example 36 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  190nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534233(WO2022081973, Example 37 | 2-(((2R)-1-(((((2R,3S,4...)
Affinity DataEC50:  260nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534234(WO2022081973, Example 38 | 2-(((2R)-1-(((((2R,3S,4...)
Affinity DataEC50:  160nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534235(WO2022081973, Example 39 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  78nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534236(WO2022081973, Example 40 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  380nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534237(WO2022081973, Example 41 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  63nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534238(WO2022081973, Example 42 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  180nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534239(WO2022081973, Example 43 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  59nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534240(WO2022081973, Example 44 | 3-((((2R)-1-(((((2R,3S,...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534241(WO2022081973, Example 45 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  82nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534242(WO2022081973, Example 46 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  26nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534243(WO2022081973, Example 47 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  32nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534244(WO2022081973, Example 48 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534245(WO2022081973, Example 49 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  23nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534246(WO2022081973, Example 54 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

Displayed 1 to 50 (of 137 total ) | Next | Last >>
Jump to: